News
NSPR
1.140
-2.56%
-0.030
Top Executive Makes Bold Move With Fresh InspireMD Stock Purchase
TipRanks · 19h ago
InspireMD CEO Marvin Slosman acquires 21,000 shares valued at $25,200
PUBT · 1d ago
InspireMD Insider Makes Bold New Bet on the Company’s Future
TipRanks · 1d ago
InspireMD director Paul Stuka buys common shares worth $87,125.56
PUBT · 1d ago
Weekly Report: what happened at NSPR last week (0504-0508)?
Weekly Report · 3d ago
InspireMD Balances Fast Growth With U.S. Setback
TipRanks · 3d ago
Insiders Make Bold Moves as InspireMD Directors Load Up on Shares
TipRanks · 5d ago
InspireMD director Scott R. Ward acquires common shares worth $102,125
PUBT · 6d ago
InspireMD director Paul Stuka acquires 7,895 shares worth $9,053.79
PUBT · 6d ago
InspireMD director Gary S. Roubin acquires $106,200 in common shares
PUBT · 6d ago
InspireMD Q1 FY26 net loss widens 22.6% to $13.69 million; revenue more than doubles to $3.4 million
PUBT · 05/07 12:54
InspireMD presents at Bank of America Securities Global Healthcare Conference
PUBT · 05/06 20:15
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Pfizer (PFE) and InspireMD (NSPR)
TipRanks · 05/06 12:20
InspireMD Price Target Cut to $3.00/Share From $4.00 by Piper Sandler
Dow Jones · 05/05 18:23
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3
Benzinga · 05/05 18:13
InspireMD price target lowered to $3 from $4 at Piper Sandler
TipRanks · 05/05 11:00
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance
Seeking Alpha · 05/04 22:44
Transcript: InspireMD Q1 2026 Earnings Conference Call
Benzinga · 05/04 21:14
InspireMD reports Q1 EPS (16c), consensus (18c)
TipRanks · 05/04 20:44
InspireMD Q1 revenue jumps 122%, beats estimates on product demand
Reuters · 05/04 20:15
More
Webull provides a variety of real-time NSPR stock news. You can receive the latest news about Inspiremd through multiple platforms. This information may help you make smarter investment decisions.
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.